+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Next Generation Sequencing Market Size, Share & Trends Analysis Report by Application (HLA Typing, Consumer Genomics), by Technology, by Workflow, by End Use, by Region, and Segment Forecasts, 2020 - 2027

  • ID: 4761224
  • Report
  • February 2020
  • Region: Global
  • 267 pages
  • Grand View Research
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • BGI
  • DNASTAR, Inc.
  • GnuBio
  • Knome, Inc.
  • Macrogen, Inc.
  • Perkin Elmer, Inc.
  • MORE
The global next generation sequencing market size is expected to reach USD 23.7 billion by 2027, expanding at a CAGR of 11.7%. Numerous advantages offered by high throughput sequencing over other genetic technologies such as sanger-seq and microarray is one of the key driving forces of the market for Next Generation Sequencing (NGS). Furthermore, increasing availability of low input DNA sampling methods that decrease the overall operational costs is anticipated to accelerate the use of next generation sequencing across various research and clinical applications.

Technology offered by New England Biolabs that employs magnetic beads in the template assembly process is anticipated to significantly improve the sample preparation protocols for next generation sequencing. Furthermore, recent technological advancements such as the use of Laboratory Information Management System (LIMS) for genome library automation allow next generation sequencing in a single day at a reasonable cost. These advancements are anticipated to proliferate the number of users of next generation sequencing over the forecast period.

This technology has captured the attention of several companies and investors operating across various domains including basic research, drug discovery and development, reproductive health, and consumer genomics. In addition, the plummeting cost and the added value of next generation sequencing data over conventional ones is anticipated to positively impact the diversification of this technology in other clinical areas, resulting into a lucrative revenue growth.

Further key findings from the report suggest:
  • In 2019, oncology was estimated as the application with the largest revenue share in the market for next generation sequencing
  • This can be attributed to the fact that the technology has been largely adopted to decipher the link between cancer and genetics
  • Moreover, NGS-based genetic testing for cancer predisposition can significantly improve the health outcome and reduce the mortality rate, thereby driving adoption in this segment
  • The targeted sequencing segment has dominated the revenue share owing to its various benefits over the whole genome segment with respect to the depth of coverage and multiplexing capacities
  • Significant price drop in sequencing the whole genome is anticipated to drive the segment at a lucrative growth rate
  • Based on workflow, sequencing accounted for the major revenue share in 2019 in the market for next generation sequencing and is anticipated to maintain its dominance over the forecast period
  • Being a key step, the end-users are making major investments in the seq-step, compared to sample preparation and data analysis
  • Moreover, the key developers are engaged in introducing new seq-platforms with enhanced capabilities and efficiency. These factors have led the segment in terms of revenue over the past years
  • Academic research entities are the largest end-users in terms of revenue generation owing to the high penetration of seq-technology in research activities
  • On the other hand, this technology is making continued growth in clinical research and within clinical settings
  • A substantial number of researchers are engaged in conducting translational research to accelerate the adoption of seq-technology in clinical diagnostics
  • North American accounted for the maximum revenue share owing to the presence of integrated platform base in the U.S.
  • Presence of Illumina, the major player of next generation sequencing market for the U.S. is another major factor that has driven the revenue share of this region in the past years
  • Asia Pacific is projected to mark fastest growth owing to the increase in number of domestic developers in China coupled with the expansion of molecular diagnostics area
  • Some major participants in the market for next generation sequencing are Illumina Inc., F Hoffman-La Roche Ltd., QIAGEN, Thermo Fisher Scientific Inc., and BGI
  • The companies are collaborating with diagnostic players to extend the use of their platforms in clinical settings
  • For instance, Illumina has partnered with China’s KingMed Diagnostics for use of its platform in oncology and hereditary disease testing.

Please note: This product will be delivered within 48 business hours after receipt of order.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • BGI
  • DNASTAR, Inc.
  • GnuBio
  • Knome, Inc.
  • Macrogen, Inc.
  • Perkin Elmer, Inc.
  • MORE
Chapter 1 Research Methodology & Scope
1.1 Information Procurement
1.1.1 Purchased database:
1.1.2 internal database
1.1.3 Secondary sources:
1.1.4 Third Party Perspective:
1.1.5 Primary Research:
1.2 Information or Data Analysis
1.3 Market Formulation & Validation
1.4 Region Wise Market Calculation
1.4.1 Region wise market: Base estimates
1.4.2 Global market: CAGR calculation
1.4.3 Region based segment share calculation

Chapter 2 Executive Summary
2.1 Next Generation Sequencing Market Outlook, 2016 - 2027
2.2 Next Generation Sequencing Market : Segment Outlook, 2016 - 2027
2.3 Next Generation Sequencing Market : Competitive Insights

Chapter 3 Next Generation Sequencing Market Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.1.2 Related/ancillary market outlook
3.2 Penetration & Growth Prospect Mapping for Applications, 2019
3.3 Penetration & Growth Prospect Mapping for Prominent Industry Players, 2019
3.4 Product Pipeline Analysis, by Stage
3.5 Cost Structure Analysis
3.6 User Perspective Analysis
3.6.1 Consumer behavior analysis
3.6.2 Market influencer analysis
3.7 Procedure Cost Analysis/Breakdown
3.8 List of Key End-users by Region, by Product, by Country
3.9 Technology Overview
3.9.1 Technology timeline
3.10 Regulatory Framework
3.10.1 Next generation sequencing reimbursement environment
3.10.1.1 Gap fill approach for reimbursement of NGS tests
3.10.1.2 Role of the commercial payers
3.10.1.2.1 Payer perspectives for developing coverage policy for Next Generation Tumor Sequencing Panels (NGTS)
3.10.1.2.2 Role of diagnostic laboratories and pathology centres
3.10.1.3 North America
3.10.1.3.1 U.S.
3.10.1.3.2 Canada
3.10.1.4 Europe
3.10.1.4.1 U.K.
3.10.1.4.2 Germany
3.10.1.4.3 Spain
3.10.1.5 Asia Pacific
3.10.1.6 Latin America
3.10.1.7 Middle East Africa
3.10.2 Next generation sequencing regulatory environment
3.11 Next Generation Sequencing Market - Market Dynamics
3.11.1 Market driver analysis
3.11.1.1 Exponentially decreasing costs for genetic sequencing
3.11.1.2 Development of companion diagnostics and personalized medicine
3.11.1.3 Rise in competition amongst prominent market entities
3.11.1.4 Rising clinical opportunity for NGS technology
3.11.1.5 Technological advancements in cloud computing and data integration
3.11.1.6 Growing healthcare expenditure supporting development of effective PM diagnostic & therapeutic procedures for cancer
3.11.1.7 Increasing prevalence of cancer
3.11.2 Market restraint analysis
3.11.2.1 Lack of computational efficiency for data management
3.11.2.2 Non-value based NGS reimbursement policy and regulation status
3.11.3 Market challenges analysis
3.11.3.1 Challenges associated with NGS implementation
3.12 Next Generation Sequencing Market Analysis Tools
3.12.1 Industry Analysis - Porter’s
3.12.1.1 Supplier power : Low bargaining power of suppliers due to the complex nature of NGS products
3.12.1.2 Buyer power: Moderate bargaining power of buyer because of a low number of approved products for genome, exome and partial sequencing
3.12.1.3 Substitution threat: Low threat of substitution owing to highly specific nature of genome sequencing
3.12.1.4 New entrants threat: Threat of new entrant is low due presence of prominent players
3.12.1.5 Competitive rivalry: High competitive rivalry due ongoing struggle among the players
3.12.2 PESTEL analysis
3.12.2.1 Political landscape
3.12.2.2 Environmental landscape
3.12.2.3 Social landscape
3.12.2.4 Technology landscape
3.12.2.5 Legal landscape
3.12.3 Major deals & strategic alliances analysis
3.12.3.1 Joint ventures
3.12.3.2 Mergers & acquisitions
3.12.3.3 Licensing & partnership
3.12.3.4 Technology collaborations
3.12.3.5 Strategic divestments
3.12.4 Market entry strategies
3.12.5 Case studies
3.13 NGS Platform Penetration Mapping, 2019
3.13.1 Next Generation Sequencing Market: Regional Market Share, 2019
3.13.2 Next Generation Sequencing North America Regulatory and Political Landscape Analysis, 2019
3.13.2.1 U.S.
3.13.2.2 Canada
3.13.3 Next Generation Sequencing Europe Regulatory and Political Landscape Analysis, 2019
3.13.3.1 U.K.
3.13.3.2 Germany
3.13.3.3 France
3.13.3.4 Spain
3.13.4 Next Generation Sequencing Asia Pacific Regulatory and Political Landscape Analysis, 2019
3.13.4.1 Japan
3.13.4.2 China
3.13.5 Next Generation Sequencing Latin America Regulatory and Political Landscape Analysis, 2019
3.13.5.1 Brazil
3.13.5.2 Mexico
3.13.5.3 Argentina
3.13.6 Next Generation Sequencing Middle East & Africa Regulatory and Political Landscape Analysis, 2019
3.13.6.1 South Africa
3.13.6.2 Qatar
3.13.6.3 Kuwait
3.13.6.4 UAE
3.13.6.5 Saudi Arabia

Chapter 4 Next Generation Sequencing Market: Competitive Analysis
4.1 Recent Developments & Impact Analysis, by Key Market Participants
4.2 Company/Competition Categorization
4.3 Vendor Landscape
4.3.1.1 List of key distributors and channel partners
4.3.1.2 Key customers
4.3.1.3 Key company market share analysis, 2019
4.3.2 Public Companies
4.3.2.1 Company market position analysis
4.3.2.2 Company market share/ranking by region
4.3.2.3 Competitive dashboard analysis
4.3.2.4 Market differentiators
4.3.2.5 Synergy analysis: Major deals & strategic alliances
4.3.3 Private Companies
4.3.3.1 List of key emerging companies
4.3.3.2 Funding outlook
4.3.3.3 Regional network map
4.3.3.4 Company market position analysis
4.3.3.5 Supplier Ranking

Chapter 5 Next Generation Sequencing Market Categorization: Technology Estimates & Trend Analysis
5.1 Definitions & Scope
5.2 Technology Market Share Analysis, 2019 & 2027
5.3 Next Generation Sequencing Market: Technology Movement Analysis, 2019 & 2027
5.4 Global Next Generation Sequencing Market, by Technology, 2016 to 2027
5.5 Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following,
5.5.1 Whole genome sequencing
5.5.1.1 Global whole genome sequencing market, 2016 - 2027 (USD Million)
5.5.2 Whole exome sequencing
5.5.2.1 Global whole exome sequencing market, 2016 - 2027 (USD Million)
5.5.3 Targeted sequencing & resequencing
5.5.3.1 Global targeted sequencing & resequencing market, 2016 - 2027 (USD Million)
5.5.3.1.1 DNA based targeted sequencing & resequencing
5.5.3.1.2 Global DNA based targeted sequencing & resequencing market, 2016 - 2027 (USD Million)
5.5.3.2 RNA-based targeted sequencing & resequencing
5.5.3.2.1 Global RNA based targeted sequencing & resequencing market, 2016 - 2027 (USD Million)

Chapter 6 Next Generation Sequencing Market Categorization: Application Estimates & Trend Analysis
6.1 Definitions & Scope
6.2 Application Market Share Analysis, 2019 & 2027
6.3 Next Generation Sequencing Market: Application Movement Analysis, 2019 & 2027
6.4 Global Next Generation Sequencing Market, by Application, 2016 to 2027
6.5 Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following,
6.5.1 Oncology
6.5.1.1 Global oncology market, 2016 - 2027 (USD Million)
6.5.1.2 Diagnostics and screening
6.5.1.2.1 Diagnostics and screening market, 2016 - 2027 (USD Million)
6.5.1.2.2 Oncology screening
6.5.1.2.2.1 Oncology screening market, 2016 - 2027 (USD Million)
6.5.1.2.2.2 Sporadic cancer screening market, 2016 - 2027 (USD Million)
6.5.1.2.2.3 Inherited cancer screening market, 2016 - 2027 (USD Million)
6.5.1.2.3 Companion diagnostics market, 2016 - 2027 (USD Million)
6.5.1.2.4 Other diagnostics market, 2016 - 2027 (USD Million)
6.5.1.3 Research studies market, 2016 - 2027 (USD Million)
6.5.2 Clinical investigation
6.5.2.1 Global clinical investigation market, 2016 - 2027 (USD Million)
6.5.2.2 Infectious diseases
6.5.2.2.1 Global infectious diseases market, 2016 - 2027 (USD Million)
6.5.2.3 Inherited diseases
6.5.2.3.1 Global inherited diseases market, 2016 - 2027 (USD Million)
6.5.2.4 Idiopathic diseases
6.5.2.4.1 Global idiopathic diseases market, 2016 - 2027 (USD Million)
6.5.2.6 Non-communicable/other diseases
6.5.2.6.1 Global non-communicable/other diseases market, 2016 - 2027 (USD Million)
6.5.3 Reproductive health
6.5.3.1 Global reproductive health market, 2016 - 2027 (USD Million)
6.5.3.2 NIPT
6.5.3.2.1 Global NIPT market, 2016 - 2027 (USD Million)
6.5.3.2.2 Global aneuploidy market, 2016 - 2027 (USD Million)
6.5.3.2.3 Global microdeletions market, 2016 - 2027 (USD Million)
6.5.3.3 PGT
6.5.3.3.1 Global NGS PGT market, 2016 - 2027 (USD Million)
6.2.3.4 New-born/genetic screening
6.5.3.4.1 Global newborn/genetic screening market, 2016 - 2027 (USD Million)
6.2.3.6 Single gene analysis
6.5.3.6.1 Single gene analysis market, 2016 - 2027 (USD Million)
6.5.4 HLA typing/immune system monitoring
6.5.4.1 Global HLA typing/immune system monitoring market, 2016 - 2027 (USD Million)
6.5.6 Metagenomics, epidemiology & drug development
6.5.6.1 Global metagenomics, epidemiology & drug development market, 2016 - 2027 (USD Million)
6.5.6 Agrigenomics & forensics
6.5.6.1 Global agrigenomics & forensics market, 2016 - 2027 (USD Million)
6.5.7 Consumer genomics
6.5.7.1 Global consumer genomics market, 2016 - 2027 (USD Million)

Chapter 7 Next Generation Sequencing Market Categorization: Workflow Estimates & Trend Analysis
7.1 Definitions & Scope
7.2 Workflow Market Share Analysis, 2019 & 2027
7.3 Next Generation Sequencing Market: Workflow Movement Analysis, 2019 & 2027
7.4 Global Next Generation Sequencing Market by Workflow, 2019 & 2027
7.5 Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following,
7.5.1 Pre-Sequencing
7.5.1.1 Global pre-sequencing market, 2016 - 2027 (USD Million)
7.5.1.2 NGS library preparation kits
7.5.1.2.1 Global NGS library preparation kits market, 2016 - 2027 (USD Million)
7.5.1.3 NGS semi-automated library preparation
7.5.1.3.1 Global NGS semi-automated library preparation market, 2016 - 2027 (USD Million)
7.5.1.4 NGS automated library preparation
7.5.1.4.1 Global NGS automated library preparation market, 2016 - 2027 (USD Million)
7.5.1.5 Clonal amplification
7.5.1.5.1 Global clonal amplification market, 2016 - 2027 (USD Million)
7.5.2 Sequencing
7.5.2.1 Global sequencing market, 2016 - 2027 (USD Million)
7.5.3 Data analysis
7.5.3.1 Global data analysis market, 2016 - 2027 (USD Million)
7.5.3.2 NGS primary data analysis
7.5.3.2.1 Global NGS primary data analysis market, 2016 - 2027 (USD Million)
7.5.3.3 NGS secondary data analysis
7.5.3.3.1 Global NGS secondary data analysis market, 2016 - 2027 (USD Million)
7.5.3.4 NGS tertiary data analysis
7.5.3.4.1 Global NGS tertiary data analysis services market, 2016 - 2027 (USD Million)

Chapter 8 Next Generation Sequencing Market Categorization: End-use Estimates & Trend Analysis
8.1 Definitions & Scope
8.2 End-use Market Share Analysis, 2019 & 2027
8.3 Next Generation Sequencing Market: End-Use Movement Analysis, 2019 & 2027
8.4 Global Next Generation Sequencing Market, by End use, 2016 to 2027
8.5 Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following,
8.5.1 Academic research
8.5.1.1 Global academic research market, 2016 - 2027 (USD Million)
8.5.2 Clinical research
8.5.2.1 Global clinical research market, 2016 - 2027 (USD Million)
8.5.3 Hospitals & clinics
8.5.3.1 Global hospitals & clinics market2016 - 2027 (USD Million)
8.5.4 Pharma & biotech entities
8.5.4.1 Global pharma & biotech entities market, 2016 - 2027 (USD Million)
8.5.5 Other users
8.5.5.1 Global other users market, 2016 - 2027 (USD Million)

Chapter 9 Next Generation Sequencing Market Categorization: Regional Estimates & Trend Analysis, by Product & Service Type, Application, Technology, Workflow, & End-use
9.1 Next generation sequencing market share by region, 2019 & 2027
9.2 Regional Market Share and Leading Players, 2019
9.2.1 North America
9.2.2 Europe
9.2.3 Asia Pacific
9.2.4 Latin America
9.2.5 Middle East & Africa
9.3 North America
9.3.1 North America next generation sequencing market, 2016 - 2027 (USD Million)
9.3.2 U.S.
9.3.2.1 U.S. next generation sequencing market, 2016 - 2027 (USD Million)
9.3.3 Canada
9.3.3.1 Canada next generation sequencing market, 2016 - 2027 (USD Million)
9.4 Europe
9.4.1 Europe next generation sequencing market, 2016 - 2027 (USD Million)
9.4.2 Germany
9.4.2.1 Germany next generation sequencing market, 2016 - 2027 (USD Million)
9.4.3 U.K.
9.4.3.1 U.K. next generation sequencing market, 2016 - 2027 (USD Million)
9.5 Asia Pacific
9.5.1 Asia Pacific next generation sequencing market, 2016 - 2027 (USD Million)
9.5.2 Japan
9.5.2.1 Japan next generation sequencing market, 2016 - 2027 (USD Million)
9.5.3 China
9.5.3.1 China next generation sequencing market, 2016 - 2027 (USD Million)
9.6 Latin America
9.6.1 Latin America next generation sequencing market, 2016 - 2027 (USD Million)
9.6.2 Brazil
9.6.2.1 Brazil next generation sequencing market, 2016 - 2027 (USD Million)
9.7 Middle East & Africa
9.7.1 Middle East & Africa next generation sequencing market, 2016 - 2027 (USD Million)
9.7.2 South Africa
9.7.2.1 South Africa next generation sequencing market, 2016 - 2027 (USD Million)

Chapter 10 Competitive Landscape
10.1 Strategy Framework
10.2 Market Participation Categorization
10.3 Next-Generation Sequencing Vendor’s Landscape
10.3.1 Champions
10.3.2 Innovators
10.3.3 Emerging players
10.3.4 Market pillars
10.4 Company Profiles
10.4.1 Illumina, Inc.
10.4.1.1 Company overview
10.4.1.2 Financial performance
10.4.1.3 Product benchmarking
10.4.1.4 Strategic initiatives
10.4.2 F. Hoffmann-La Roche Ltd.
10.4.2.1 Company overview
10.4.2.2 Financial performance
10.4.2.3 Product benchmarking
10.4.2.4 Strategic initiatives
10.4.3 Agilent Technologies, Inc.
10.4.3.1 Company overview
10.4.3.2 Financial performance
10.4.3.3 Product benchmarking
10.4.3.4 Strategic initiatives
10.4.4 PierianDx
10.4.4.1 Company overview
10.4.4.1.1 Tute Genomics
10.4.4.1.2 Knome, Inc.
10.4.4.2 Financial performance
10.4.4.3 Product benchmarking
10.4.4.4 Strategic initiatives
10.4.5 Genomatix GmbH
10.4.5.1 Company overview
10.4.5.2 Financial performance
10.4.5.3 Product benchmarking
10.4.5.4 Strategic initiatives
10.4.6 Eurofins GATC Biotech GmbH
10.4.6.1 Company overview
10.4.6.2 Financial performance
10.4.6.3 Product benchmarking
10.4.6.4 Strategic initiatives
10.4.7 Oxford Nanopore Technologies
10.4.7.1 Company overview
10.4.7.2 Financial performance
10.4.7.3 Product benchmarking
10.4.7.4 Strategic initiatives
10.4.8 Macrogen, Inc.
10.4.8.1 Company overview
10.4.8.2 Financial performance
10.4.8.3 Product benchmarking
10.4.8.4 Strategic initiatives
10.4.9 Thermo Fisher Scientific, Inc.
10.4.9.1 Company overview
10.4.9.1.1 Life Technologies Corp.
10.4.9.2 Financial performance
10.4.9.3 Product benchmarking
10.4.9.4 Strategic initiatives
10.4.10 DNASTAR, Inc.
10.4.10.1 Company overview
10.4.10.2 Financial Performance
10.4.10.3 Product benchmarking
10.4.10.4 Strategic initiatives
10.4.11 Biomatters Ltd.
10.4.11.1 Company overview
10.4.11.2 Financial performance
10.4.11.3 Product benchmarking
10.4.11.4 Strategic initiatives
10.4.12 QIAGEN
10.4.12.1 Company overview
10.4.12.1.1 Ingenuity
10.4.12.1.2 CLC Bio
10.4.12.2 Financial performance
10.4.12.3 Product benchmarking
10.4.12.4 Strategic initiatives
10.4.13 BGI
10.4.13.1 Company overview
10.4.13.1.1 Complete Genomics Incorporated
10.4.13.2 Financial performance
10.4.13.3 Product benchmarking
10.4.13.4 Strategic initiatives
10.4.14 Perkin Elmer, Inc.
10.4.14.1 Company overview
10.4.14.2 Financial performance
10.4.14.3 Product benchmarking
10.4.14.4 Strategic initiatives
10.4.15 Pacific Biosciences of California, Inc.
10.4.15.1 Company overview
10.4.15.2 Financial performance
10.4.15.3 Product benchmarking
10.4.15.4 Strategic initiatives
10.4.16 Partek Incorporated
10.4.16.1 Company overview
10.4.16.2 Financial performance
10.4.16.3 Product benchmarking
10.4.16.4 Strategic initiatives
10.4.17 Bio-Rad Laboratories, Inc.
10.4.17.1 Company overview
10.4.17.2 GnuBio
10.4.17.2.1 Company overview
10.4.17.3 Financial performance
10.4.17.4 Product benchmarking
10.4.17.5 Strategic initiatives
10.4.18 Myriad Genetics, Inc.
10.4.18.1 Company overview
10.4.18.2 Financial performance
10.4.18.3 Product benchmarking
10.4.18.4 Strategic initiatives
10.4.19 Hologic, Inc. (Gen-Probe Incorporated)
10.4.19.1 Company overview
10.4.19.2 Financial performance
10.4.19.3 Product benchmarking
10.4.19.4 Strategic initiatives
10.4.20 Horizon Discovery Group plc
10.4.20.1 Company overview
10.4.20.2 Financial performance
10.4.20.3 Product benchmarking
10.4.20.4 Strategic initiatives
10.4.21 LGC Limited
10.4.21.1 Company overview
10.4.21.2 SeraCare
10.4.21.2.1 Company overview
10.4.21.3 Financial performance (LGC Limited)
10.4.21.3.1 Financial performance
10.4.21.4 Product benchmarking
10.4.21.5 Strategic initiatives
10.4.22 Vela Diagnostics
10.4.22.1 Company overview
10.4.22.2 Financial performance
10.4.22.3 Product benchmarking
10.4.22.4 Strategic initiatives
10.5 List of Companies


*Full List of Tables and Figures Available on Enquiry.
Note: Product cover images may vary from those shown
3 of 3
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Agilent Technologies, Inc.
  • PierianDx
  • Tute Genomics
  • Knome, Inc.
  • Genomatix GmbH
  • Eurofins GATC Biotech GmbH
  • Oxford Nanopore Technologies
  • Macrogen, Inc.
  • Thermo Fisher Scientific, Inc.
  • Life Technologies Corp.
  • DNASTAR, Inc.
  • Biomatters Ltd.
  • QIAGEN
  • Ingenuity
  • CLC Bio
  • BGI
  • Complete Genomics Incorporated
  • Perkin Elmer, Inc.
  • Pacific Biosciences of California, Inc.
  • Partek Incorporated
  • Bio-Rad Laboratories, Inc.
  • GnuBio
  • Myriad Genetics, Inc.
  • Hologic, Inc. (Gen-Probe Incorporated)
  • Horizon Discovery Group plc
  • LGC Limited
  • SeraCare
  • Vela Diagnostics
Note: Product cover images may vary from those shown
Adroll
adroll